The state of North Carolina currently has 6 active clinical trials seeking participants for Hepatitis B research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Recruiting
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/22/2024
Locations: Chapel Hill CRS, Chapel Hill, North Carolina +1 locations
Conditions: Hepatitis B, HIV Infections
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Recruiting
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/09/2024
Locations: Duke Liver Center, Durham, North Carolina
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis
Liver Cirrhosis Network Cohort Study
Recruiting
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Duke Liver Center, Durham, North Carolina
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/28/2023
Locations: Digestive Health Partners, Asheville, North Carolina +1 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.
Recruiting
The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is provided to the Registry prospectively (prior to the outcome of pregnancy being known) through their health care provider, with fo... Read More
Gender:
Female
Ages:
Between 12 years and 60 years
Trial Updated:
11/20/2023
Locations: Registry Coordinating Center, Wilmington, North Carolina
Conditions: HIV Infections, Hepatitis B
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Recruiting
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: UNC Liver Center, Chapel Hill, North Carolina
Conditions: Hepatitis B, Hepatitis, Liver Diseases